Kuros Biosciences AG

EQS-Adhoc: Kuros Biosciences Ltd. appoints Chief Medical Officer


EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel
Kuros Biosciences Ltd. appoints Chief Medical Officer

08.03.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Kuros Biosciences Ltd. appoints Chief Medical Officer

Schlieren (Zurich), Switzerland, March 8, 2016 - Kuros Biosciences Ltd. ("Kuros"
or the "Company"), announced today that Dr. Virginia Jamieson has been appointed
Chief Medical Officer and member of the Executive Board with immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has
considerable experience in early and late stage clinical development, product
registration and medical affairs. Dr. Jamieson received her medical degree at
Edinburgh University and obtained a postgraduate fellowship in anesthesia from
the Royal College of Surgeons in London. In addition, she has a diploma from the
Faculty of Pharmaceutical Medicine where she has also been an appraiser for
revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already
worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical
Officer and is therefore very familiar with Kuros' products.

Didier Cowling, CEO of Kuros, said: "We are delighted to have Virginia join us
again. Her wealth of experience, both in the surgical field and pharmaceutical
and medical industry, coupled with her deep knowledge of Kuros' products, makes
this a key appointment for us."

For further information, please contact:

Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@kuros.ch

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for
tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the SIX
Swiss Exchange Ltd under the symbol KURN.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider statements
that include the words "will" or "expect" or the negative of those words or
other similar words to be uncertain and forward-looking. Factors that may cause
actual results to differ materially from any future results expressed or implied
by any forward-looking statements include scientific, business, economic and
financial factors, Against the background of these uncertainties, readers should
not rely on forward-looking statements. The Company assumes no responsibility
for updating forward-looking statements or adapting them to future events or
developments.

www.kuros.ch


End of ad hoc announcement

+++++
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=CXTXQEOIJL
Document title: Kuros_CMO_160308

--------------------------------------------------------------------------------
08.03.2016 News transmitted by EQS Schweiz AG. www.eqs.com - news archive:
http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.
--------------------------------------------------------------------------------

Language: English

Company:  Kuros Biosciences AG

          Wagistrasse 25

          8952  Schlieren

          Switzerland

Phone:    +41 44 733 4747

Fax:      +41 44 733 4740

E-mail:info@kuros.ch

Internet: www.kuros.ch

ISIN:     CH0011025217

Valor:    -

Listed:   Foreign Exchange(s) SIX


End of News EQS Group News Service
--------------------------------------------------------------------------------
443197  08.03.2016 
 



Weitere Meldungen: Kuros Biosciences AG

Das könnte Sie auch interessieren: